⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752803 | 0.80 | KMT2A (0.47) | — | |
| Methyl Alcohol SCHEMBL28357518 | 0.79 | KMT2A (0.43) | — | |
| SCHEMBL2170819 | 0.78 | — | — | |
| SCHEMBL27983255 | 0.76 | — | — | |
| SCHEMBL2481828 | 0.76 | — | — | |
| SCHEMBL2009396 | 0.76 | — | — | |
| SCHEMBL10715836 | 0.76 | — | — | |
| SCHEMBL954218 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL26978407 | 0.76 | KMT2A (0.44) | — | |
| SCHEMBL10044969 | 0.76 | PIK3CD (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370615-A1 | Prevention of Illicit Manufacture of Methamphetamine from Pseudoephedrine Using Food Flavor Excipients | Satara Pharmaceuticals (US) | 2022-11-24 | — | — | US | claimed |
| WO-2009053448-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | claimed |
| EP-2016061-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | Glaxo Group Limited (GB) | 2009-01-21 | — | — | EP | claimed |
| WO-2007122241-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | claimed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117460722-A | Nicotinamide RIPK1 inhibitors | 艾伯维公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2003089419-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-0915847-A4 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
| EP-0915847-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004526-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1998-02-05 | — | — | WO | disclosed |